- Home
- SOPH vs OCGN Comparison
SOPH vs OCGN Comparison
Compare SOPH & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | OCGN |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 387.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOPH | OCGN |
|---|---|---|
| Price | $4.80 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | 56.8K | ★ 4.0M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,297,000.00 | $5,370,000.00 |
| Revenue This Year | $18.32 | $35.93 |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.66 | ★ 14.26 |
| 52 Week Low | $2.58 | $0.52 |
| 52 Week High | $5.30 | $1.90 |
Technical Indicators
Market Signals| Indicator | SOPH | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 63.05 |
| Support Level | $4.52 | $1.32 |
| Resistance Level | $4.82 | $1.53 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 66.96 | 96.15 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").